• patients
  • The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), failed to demonstrate a difference in all-cause mortality or nonfatal myocardial infarction/fatal coronary heart disease rates between patients receiving pravastatin 40 mg daily (a common starting dose) and those receiving usual care. (wikipedia.org)
  • These trials indicate pravastatin is well tolerated and displays few noncardiovascular abnormalities in patients. (wikipedia.org)
  • decrease
  • Large decrease in pravastatin bioavailability. (drugs.com)
  • Pravastatin is used with diet, weight-loss, and exercise to reduce the risk of heart attack and stroke and to decrease the chance that heart surgery will be needed in people who have heart disease or who are at risk of developing heart disease. (empowher.com)
  • small
  • Although previous small studies of pravastatin in this field have been performed, none has done so in a randomised placebo controlled trial taking into account all the relevant measures. (clinicaltrials.gov)
  • known
  • Initially known as CS-514, pravastatin is a derivative of ML236B (compactin), which was identified in a fungus called Penicillium citrinum in the 1970s by researchers of the Sankyo Pharma Inc. It is being marketed outside Japan by the pharmaceutical company Bristol-Myers Squibb. (wikipedia.org)
  • hours
  • if you are taking cholestyramine (Questran) or colestipol (Cholestid), take them 4 hours before or 1 hour after pravastatin. (empowher.com)